Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unresectable Hepatocellular Carcinoma × tremelimumab × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 34 Carcinoma, Non-Small-Cell Lung 22 Melanoma 18 Squamous Cell Carcinoma of Head and Neck 16 Colorectal Neoplasms 15 Urinary Bladder Neoplasms 11 Lung Neoplasms 10 Liver Neoplasms 10 Breast Neoplasms 10 Biliary Tract Neoplasms 10 Small Cell Lung Carcinoma 9 Prostatic Neoplasms 9 Diabetes Mellitus, Insulin-Dependent, 12 9 Carcinoma, Renal Cell 9 Neoplasms 7 Cholangiocarcinoma 7 Pancreatic Neoplasms 6 Ovarian Neoplasms 6 Head and Neck Neoplasms 6 Neoplasm Metastasis 5 Mesothelioma, Malignant 5 Fallopian Tube Neoplasms 5 Adenocarcinoma Of Esophagus 5 Uterine Cervical Neoplasms 4 Stomach Neoplasms 4 Recurrence 3 Mesothelioma 3 Kidney Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Endometrial Neoplasms 3

Interventions

tremelimumab 1 durvalumab 1 atezolizumab 1 Therapeutics 1 Immunotherapy 1 Bumetanide 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06117891 2025-11-12

REFINE-IO

Bayer

Gastrointestinal

Unresectable Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡